$PLX
Protalix BioTherapeutics, Inc.

2017 Q4 Form 10-Q Financial Statement

#000114420417057290 Filed on November 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2016 Q3
Revenue $4.310M $4.670M
YoY Change 107.21% 249.55%
Cost Of Revenue $1.550M $4.248M
YoY Change -20.51% 1804.93%
Gross Profit $2.750M $422.0K
YoY Change 2015.38% -62.08%
Gross Profit Margin 63.81% 9.04%
Selling, General & Admin $3.340M $2.014M
YoY Change 6.37% -6.89%
% of Gross Profit 121.45% 477.25%
Research & Development $9.780M $6.353M
YoY Change 45.75% 25.36%
% of Gross Profit 355.64% 1505.45%
Depreciation & Amortization $450.0K $480.0K
YoY Change -8.16% -18.64%
% of Gross Profit 16.36% 113.74%
Operating Expenses $12.33M $8.367M
YoY Change 39.32% 15.71%
Operating Profit -$9.580M -$6.648M
YoY Change 9.86% 32.91%
Interest Expense -$2.400M -$640.0K
YoY Change -69.89% -36.63%
% of Operating Profit
Other Income/Expense, Net -$642.0K
YoY Change -36.62%
Pretax Income -$13.31M -$7.290M
YoY Change 408.02% 21.1%
Income Tax
% Of Pretax Income
Net Earnings -$13.31M -$7.290M
YoY Change 408.02% 90.84%
Net Earnings / Revenue -308.82% -156.1%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.95 -$0.73
COMMON SHARES
Basic Shares Outstanding 139.7M shares 99.81M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.20M $51.30M
YoY Change -19.12% 50.0%
Cash & Equivalents $51.16M $51.32M
Short-Term Investments
Other Short-Term Assets $1.934M $1.400M
YoY Change -16.67% -48.45%
Inventory $7.833M $4.900M
Prepaid Expenses $433.0K
Receivables $1.721M $2.096M
Other Receivables $0.00 $0.00
Total Short-Term Assets $62.65M $59.60M
YoY Change -12.82% 24.49%
LONG-TERM ASSETS
Property, Plant & Equipment $7.676M $9.100M
YoY Change -11.8% -8.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.900M $1.700M
YoY Change 11.76% 0.0%
Total Long-Term Assets $9.563M $10.90M
YoY Change -7.87% -6.16%
TOTAL ASSETS
Total Short-Term Assets $62.65M $59.60M
Total Long-Term Assets $9.563M $10.90M
Total Assets $72.21M $70.50M
YoY Change -12.2% 18.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.310M $4.000M
YoY Change 24.2% -2.44%
Accrued Expenses $4.802M
YoY Change 34.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.900M
YoY Change -89.05%
Total Short-Term Liabilities $22.75M $10.30M
YoY Change -65.64% -54.93%
LONG-TERM LIABILITIES
Long-Term Debt $51.30M $72.40M
YoY Change 117.37% 6.78%
Other Long-Term Liabilities $5.051M $2.800M
YoY Change 17.44% -92.51%
Total Long-Term Liabilities $78.92M $75.20M
YoY Change 203.63% -28.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.75M $10.30M
Total Long-Term Liabilities $78.92M $75.20M
Total Liabilities $101.7M $85.60M
YoY Change 10.27% -33.13%
SHAREHOLDERS EQUITY
Retained Earnings -$296.1M
YoY Change 39.24%
Common Stock $266.6M
YoY Change 31.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$29.46M -$15.10M
YoY Change
Total Liabilities & Shareholders Equity $72.21M $70.50M
YoY Change -12.2% 18.5%

Cashflow Statement

Concept 2017 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$13.31M -$7.290M
YoY Change 408.02% 90.84%
Depreciation, Depletion And Amortization $450.0K $480.0K
YoY Change -8.16% -18.64%
Cash From Operating Activities $17.59M -$3.440M
YoY Change -339.65% -60.28%
INVESTING ACTIVITIES
Capital Expenditures $290.0K $150.0K
YoY Change 141.67% 15.38%
Acquisitions
YoY Change
Other Investing Activities $250.0K $90.00K
YoY Change -292.31% -325.0%
Cash From Investing Activities -$30.00K -$70.00K
YoY Change -87.5% -58.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 17.59M -3.440M
Cash From Investing Activities -30.00K -70.00K
Cash From Financing Activities 0.000 0.000
Net Change In Cash 17.56M -3.510M
YoY Change 44.88% -60.25%
FREE CASH FLOW
Cash From Operating Activities $17.59M -$3.440M
Capital Expenditures $290.0K $150.0K
Free Cash Flow $17.30M -$3.590M
YoY Change -331.9% -59.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Income Loss
NetIncomeLoss
-26741000 USD
us-gaap Depreciation
Depreciation
1489000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
375000 USD
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
-31000 USD
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
3000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1358000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-907000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
367000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
732000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-7000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
431000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-25054000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76374000 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51320000 USD
us-gaap Net Income Loss
NetIncomeLoss
-70135000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
291000 USD
us-gaap Depreciation
Depreciation
1469000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-13000 USD
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
54000 USD
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
21000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-837000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6467000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2234000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8698000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
681000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
336000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
68000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1419000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
289000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-29799000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24749000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-27700000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-26552000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-11000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
116000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24760000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27584000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-725000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1085000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-189000 USD
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-38061000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
333000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1710000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
10961000 USD
plx Gain Loss On Conversion Of Convertible Notes
GainLossOnConversionOfConvertibleNotes
-587000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-291000 USD
plx Gain Loss On Conversion Of Convertible Notes
GainLossOnConversionOfConvertibleNotes
0 USD
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
plx Issuance Of Shares For Interest Payment Regarding Conversion Of Convertible Notes
IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes
1111000 USD
plx Issuance Of Shares For Interest Payment Regarding Conversion Of Convertible Notes
IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes
0 USD
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
666000 USD
us-gaap Interest Paid Net
InterestPaidNet
3105000 USD
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
76195921 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19572040 shares
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19484667 shares
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
80696070 shares
CY2017Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4153000 USD
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2591000 USD
CY2017Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2834000 USD
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2259000 USD
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
395000 USD
CY2017Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
492000 USD
CY2016Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
327000 USD
CY2017Q3 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
211000 USD
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
209000 USD
us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
373000 USD
us-gaap Disposal Group Including Discontinued Operation Gross Profit Loss
DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
-164000 USD
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
25000 USD
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
-189000 USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
5911000 USD
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
9542000 USD
CY2017Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.045 pure
us-gaap Revenues
Revenues
16773000 USD
us-gaap Revenues
Revenues
7118000 USD
CY2017Q3 us-gaap Revenues
Revenues
7526000 USD
CY2016Q3 us-gaap Revenues
Revenues
4670000 USD
us-gaap Cost Of Revenue
CostOfRevenue
13677000 USD
us-gaap Cost Of Revenue
CostOfRevenue
6446000 USD
CY2017Q3 us-gaap Cost Of Revenue
CostOfRevenue
6066000 USD
CY2016Q3 us-gaap Cost Of Revenue
CostOfRevenue
4248000 USD
us-gaap Gross Profit
GrossProfit
3096000 USD
us-gaap Gross Profit
GrossProfit
672000 USD
CY2017Q3 us-gaap Gross Profit
GrossProfit
1460000 USD
CY2016Q3 us-gaap Gross Profit
GrossProfit
422000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22389000 USD
plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
4800000 USD
CY2017Q3 plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
729000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23700000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7118000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6353000 USD
plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
2545000 USD
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99821970 shares
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
10873000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
697000 USD
CY2016Q3 plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
1297000 USD
plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
19844000 USD
plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
18900000 USD
CY2017Q3 plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
6389000 USD
CY2016Q3 plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
5056000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8187000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6215000 USD
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2836000 USD
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2014000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-24935000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-24443000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7765000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6648000 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8809000 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2715000 USD
CY2017Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
3680000 USD
CY2016Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
910000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1670000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
606000 USD
CY2017Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
8000 USD
CY2016Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
268000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-45200000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2109000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3672000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-642000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2017Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2016Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2017Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11437000 USD
CY2016Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-7290000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-11437000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-7290000 USD
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.27
CY2016Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.07
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
128223722 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99766245 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
132549001 shares
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
68000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
USD
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
-15103000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
291000 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
8781000 USD
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
1315000 USD
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
43634000 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
plx Debt Instrument Maturity Year
DebtInstrumentMaturityYear
2022
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Protalix BioTherapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001006281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
PLX
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
139727673 shares
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
642000 USD
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.55
CY2017Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.09
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
7668000 USD
us-gaap Interest Paid Net
InterestPaidNet
2613000 USD
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1300000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD

Files In Submission

Name View Source Status
0001144204-17-057290-index-headers.html Edgar Link pending
0001144204-17-057290-index.html Edgar Link pending
0001144204-17-057290.txt Edgar Link pending
0001144204-17-057290-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
plx-20170930.xml Edgar Link completed
plx-20170930.xsd Edgar Link pending
plx-20170930_cal.xml Edgar Link unprocessable
plx-20170930_def.xml Edgar Link unprocessable
plx-20170930_lab.xml Edgar Link unprocessable
plx-20170930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv478307_10q.htm Edgar Link pending
tv478307_ex31-1.htm Edgar Link pending
tv478307_ex31-2.htm Edgar Link pending
tv478307_ex32-1.htm Edgar Link pending
tv478307_ex32-2.htm Edgar Link pending